Agios

$31.03 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Agios

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company's lead product candidate in its genetically defined disease (GDD) portfolio, mitapivat, is an activator for the treatment of hemolytic anemias. The Company’s clinical candidate, mitapivat, is in Phase III studies which is developed for the treatment of pyruvate kinase (PK), deficiency, thalassemia, and sickle cell disease (SCD). The Company is also developing AG-946, a clinical-stage, next-generation oral activator of pyruvate kinase R (PKR) enzymes, which is in Phase I clinical study. The mitapivat is an orally available small molecule and a potent activator of the PKR enzymes.

Stock Analysis

last close $31.14
1-mo return -8.3%
3-mo return -29.7%
avg daily vol. 422.66T
52-week high 62.16
52-week low 29.21
market cap. $1.8B
forward pe 1.2
annual div. -
roe 170.8%
ltg forecast -
dividend yield -
annual rev. $44M
inst own. -
baraka

Subscribe now for daily local and international financial news

Subscribe